Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Minit Jalan Shah
Observed names:
M. Shah,
Minit J. Shah,
Minit Shah
Institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital,
Advanced Centre for Treatment, Research and Education in Cancer
Observed institutions:
Amgen (United States),
Homi Bhabha National Institute,
Tata Memorial Hospital,
Advanced Centre for Treatment, Research and Education in Cancer,
Mahamana Pandit Madan Mohan Malaviya Cancer Centre
ORCID:
0000-0002-0979-9555
Observed ORCID:
0000-0002-0979-9555
OpenAlex ID:
A5102377103
Uniqueness of lung cancer in Southeast Asia
2024
·
Vanita Noronha
, Atul Budukh
, et al.
·
The Lancet Regional Health - Southeast Asia
·
57
COVID-19 vaccine uptake and vaccine hesitancy in Indian patients with cancer: A questionnaire-based survey
2021
·
Vanita Noronha
, George Abraham
, et al.
·
Cancer Research Statistics and Treatment
·
45
COVID‐19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment
2020
·
Anant Ramaswamy
, Lingaraj Nayak
, et al.
·
Cancer Medicine
·
43
PDF
G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer
2022
·
Minit Shah
, Vanita Noronha
, et al.
·
Journal of Geriatric Oncology
·
33
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake
2020
·
Vikas Ostwal
, Sandip Basu
, et al.
·
Neuroendocrinology
·
26
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
2026
·
Vanita Noronha
, Vijay Patil
, et al.
·
Journal of Clinical Oncology
·
25
Genomic Profiling of Driver Gene Alterations in Patients With Non–Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients
2025
·
Minit Shah
, Vanita Noronha
, et al.
·
Clinical Lung Cancer
·
16
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients
2024
·
Prerana Jha
, Asim Joshi
, et al.
·
Clinical Lung Cancer
·
16
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer
2025
·
Shivani Sharma
, Vanita Noronha
, et al.
·
JCO Global Oncology
·
14
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial
2024
·
Vanita Noronha
, Vijay Patil
, et al.
·
JAMA Oncology
·
14
Cabozantinib: A narrative drug review
2023
·
Vivek K. Srigadha
, Kumar Prabhash
, et al.
·
Cancer Research Statistics and Treatment
·
14
Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer
2024
·
Vanita Noronha
, Vijay Patil
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
13
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC
2023
·
Vanita Noronha
, Nandini S. Menon
, et al.
·
JTO Clinical and Research Reports
·
12
PDF
Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinoma
2024
·
Vanita Noronha
, Vijay Maruti Patil
, et al.
·
JNCI Journal of the National Cancer Institute
·
10
Under-representation of older Indian persons with cancer in clinical trials
2024
·
Vanita Noronha
, Vijay Patil
, et al.
·
BMJ Oncology
·
10
PDF
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience
2025
·
Prerana Jha
, Rohit Mishra
, et al.
·
The Journal of Liquid Biopsy
·
9
PDF
Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/ GEJ cancer
2024
·
Vanita Noronha
, Vijay Maruti Patil
, et al.
·
International Journal of Cancer
·
8
Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: real world data
2024
·
Vanita Noronha
, Harsh Sahu
, et al.
·
ecancermedicalscience
·
8
Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial
2025
·
Vanita Noronha
, Avani Chawda
, et al.
·
Journal of the Egyptian National Cancer Institute
·
7
PDF
Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and beyond setting (DELII: Development of Low dose Immunotherapy in India).
2025
·
Vanita Noronha
, Nandini Sharrel Menon
, et al.
·
Journal of Clinical Oncology
·
7
PDF
Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in India
2024
·
Vanita Noronha
, Laboni Sarkar
, et al.
·
ecancermedicalscience
·
7
PDF
Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism
2025
·
Vaishakhi Trivedi
, Hitesh Kore
, et al.
·
JCO Global Oncology
·
6
PDF
Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis
2023
·
Anant Ramaswamy
, Darshit Shah
, et al.
·
The Indian Journal of Medical Research
·
6
Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
2026
·
Minit Jalan Shah
, Vanita Noronha
, et al.
·
Journal of Clinical Oncology
·
5
PDF
Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial
2026
·
Vanita Noronha
, Minit Shah
, et al.
·
JCO Global Oncology
·
5
PDF
Show more works
View as search
Works count:
112
Citation count:
518
H-index:
12
I10-index:
15
Year
Topic
Type